On July 7, 2026 OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, reported that it has entered into a strategic collaboration agreement with LG Chem, a leading global company that specializes in life sciences as one of its core businesses. The strategic alliance is structured to accelerate joint efforts to identify, evaluate and develop novel oncology assets from China.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaboration brings together OTR’s proprietary R&D platform and deep connection with China’s life science ecosystem, along with LG Chem’s global development expertise and commercial infrastructure. Together, the companies will establish a partnership for discovering, evaluating, and advancing innovative oncology assets from China to patients worldwide.
Under this strategic framework, OTR will identify and conduct initial technical assessment of promising oncology programs aligned with LG Chem’s strategic priorities through its regional scientific network and business development capabilities, followed by joint evaluation and licensing by both companies. OTR will lead preclinical and early clinical development by leveraging China’s speed, scientific excellence, and capital-efficient R&D environment, while LG Chem will take a leading role in ex-China clinical development, regulatory strategy, and commercialization.
Under the terms of each program-specific agreement, OTR will receive upfront payments and be entitled to global development and regulatory milestone payments. In addition, OTR has the option to participate in global development and obtain a share of global rights of programs entering late-stage clinical development. Through this long-term partnership the companies aim to accelerate the translation of innovative science into globally competitive medicines while creating a sustainable pipeline of differentiated oncology therapies for patients with significant unmet medical needs.
Dr. Son Ji-woong, President of LG Chem Life Sciences Company, stated:
"This collaboration with OTR strengthens our ability to systematically identify and evaluate promising assets emerging from China, which is becoming an emerging center of biopharmaceutical innovation. By securing high-potential assets at an early stage and advancing them jointly with our partner through future development opportunities, we aim to enhance our global competitiveness and improve patient access to innovative treatments."
Dr. Zhui Chen, Founder and Chief Executive Officer of OTR Therapeutics, commented:
"We are very delighted to collaborate with LG Chem to unlock the immense innovation potential residing within the Chinese biopharma ecosystem. By combining our agile R&D and business development capability with LG Chem’s robust clinical and commercial infrastructure, we are creating an accelerated pathway to transform early-stage breakthroughs into highly differentiated, clinically impactful therapies for patients worldwide."
(Press release, OTR Therapeutics, JUL 7, 2026, View Source [SID1234669091])